Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, Illumina Extend Supply Deal

NEW YORK (GenomeWeb News) – Sequenom today said that it has extended the term of its supply agreement with Illumina from three to five years.

The pact now terminates in July 2016. Further terms of the agreement were not disclosed.

Under the terms of the deal, signed last July, Sequenom and its subsidiaries agreed to purchase sequencing equipment and consumables from Illumina for use in developing its non-invasive trisomy 21 test. In addition, the firms said at the time that they intend to work collaboratively toward the submission of regulatory clearance of an in vitro diagnostic test for detecting fetal chromosomal abnormalities.

Sequenom launched its MaterniT21 test, which employs Illumina's HiSeq platform, in October.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.